Finance

Lists
Why is XGN down 3.19%?
Dive Deeper
XGN:NASDAQ
Exagen Inc
$8.19
-3.19%
(-0.27) 1D
$8.10
-1.10% (-0.090)
Pre-market
Closed: Oct 6, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for XGN...
Open
$8.53
High
$8.70
Low
$8.09
Mkt. cap
191.60M
Avg. vol.
274.38K
Volume
0.00
52-wk high
$12.23
52-wk low
$2.59
EPS
-$0.81
Beta
2.12
Shares outstanding
24.22M
No. of employees
218
Open
$8.53
High
$8.70
Low
$8.09
Mkt. cap
191.60M
Avg. vol.
274.38K
Volume
0.00
52-wk high
$12.23
52-wk low
$2.59
EPS
-$0.81
Beta
2.12
Shares outstanding
24.22M
No. of employees
218
News stories
From web sources and news partners
About Exagen Inc
CEO-
Employees218
Founded2002
HeadquartersVista, California, United States
SectorBiotechnology
Websiteexagen.com
Analyst ratings
Based on 5 analysts giving stock ratings to XGN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for XGN in the last 3 months.
Highest
Current $8.19
$12.00 (+46.52%)
Average
$10.20 (+24.54%)
Lowest
$9.00 (+9.89%)
Analyst
Recommendation
Action
Price target
Projected
Date
Max Masucci
Roth MKM
Buy
Maintained
$11.00
+34.3%
09/22/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$12.00
+46.5%
09/11/2026
Anderson Schock
B. Riley Securities
Buy
Reiterated
$12.00
+46.5%
08/05/2026
Mark Massaro
BTIG
Buy
Reiterated
$9.00
+9.9%
08/05/2026
Kyle Mikson CFA
Canaccord Genuity
Buy
Maintained
$9.00
+9.9%
08/05/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$10.00
+22.1%
08/04/2026
Unknown Analyst
Roth MKM
Buy
Initiated
$8.00
-2.3%
06/24/2026
Andrew Brackmann
William Blair
Buy
Reiterated
-
-
05/12/2026
William Bonello
Craig-Hallum
Buy
Reiterated
$10.00
+22.1%
03/11/2026
Paul Knight
KeyBanc
Buy
Maintained
$10.00
+22.1%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
17.24M
16.63M
17.31M
19.94M
Cost of goods sold
7.17M
7.42M
7.10M
7.72M
Cost of revenue
7.17M
7.42M
7.10M
7.72M
Research and development expenses
1.73M
1.76M
1.55M
1.43M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.44M
12.42M
12.07M
12.51M
Operating expense
13.18M
14.18M
13.62M
13.94M
Total operating expenses
20.34M
21.61M
20.72M
21.66M
Operating income
-3.10M
-4.98M
-3.41M
-1.72M
Other non operating income
-
-
-132.00K
153.00K
EBT including unusual items
-7.09M
-4.66M
-3.93M
-3.20M
EBT excluding unusual items
-4.42M
-6.26M
-4.81M
-2.77M
Income tax expense
1.00K
13.00K
36.00K
-
Effective tax rate
-0.01%
-0.28%
-0.92%
-
Other operating expenses
-
-
-
-
Net income
-7.09M
-4.67M
-3.97M
-3.20M
Net profit margin
-41.10%
-28.10%
-22.92%
-16.03%
Earnings per share
-0.31
-0.27
-0.20
-0.11
Interest and investment income
3.00K
43.00K
-
-
Interest expense
-1.32M
-1.33M
-1.27M
-1.20M
Net interest expenses
-1.32M
-1.29M
-1.27M
-1.20M
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.49M
-4.38M
-2.82M
-1.09M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps